18 results about "Freund's adjuvant" patented technology

The invention relates to the field of vaccines, in particular to application of a bacillus calmette-guerin vaccine and a complete freund's adjuvant in preparation of tuberculosis prevention vaccines. The invention provides a novel inoculation strategy of subcutaneous combined inoculation of the bacillus calmette guerin vaccine and the complete freund's adjuvant, the safety consistent with that of the existing tuberculosis prevention vaccine in the clinical stage is achieved, and the immune protection effect higher than that of the existing tuberculosis prevention vaccine in the clinical stage and the preclinical research stage is achieved. The compound is expected to be used as a novel tuberculosis vaccine for preventing tuberculosis.

The invention belongs to the technical field of medicine, and discloses application of SHLP2 in preparation of medicine for relieving and treating acute and chronic inflammatory pain, and the amino acid sequence of SHLP2 polypeptide is MGVKFFTLSTRFFPSVQRAVPLWTNS. After the SHLP2 polypeptide is treated in an intrathecal (5 [mu] g / 10 [mu] g / 20 [mu] g) injection mode, the SHLP2 polypeptide shows a good treatment effect in an acute inflammation pain model induced by formalin and capsaicin and a chronic inflammation pain model induced by carrageenan and a complete Freund's adjuvant. The SHLP2 is utilized to target a mitochondrial genome, the effect of relieving acute and chronic inflammatory pain is achieved in a central sheath injection mode, and a target different from a traditional analgesic drug can be searched for treatment of the acute and chronic inflammatory pain.

The invention belongs to the technical field of immunobiology, and particularly relates to a composite antigen polypeptide and an echinococcosis vaccine, and the composite antigen polypeptide comprises an amino acid sequence having more than 80% of homology with the amino acid sequence of MHC-II P1, MHC-II P2 or MHC-I P3. According to the invention, a plurality of antigen epitopes are connected by adopting a linker, so that the composite polypeptide FL46 is successfully constructed, and the immunogenicity of the epitopes is enhanced; according to the invention, the Freund adjuvant and the polypeptide FL46 are jointly combined to form the FL46 polypeptide Freund adjuvant vaccine, the protection effect of the vaccine on mouse echinococcosis granulosa is verified, and a remarkable capsule reducing effect is achieved.

The invention belongs to the technical field of biology, and relates to a construction method of a renal tubular interstitial nephritis-uveitis syndrome mouse model. Comprising the following steps: anesthetizing a mouse; carrying out subcutaneous injection on photoreceptor intercellular vitamin A binding proteins and a complete Freund's adjuvant on the front neck, the thighs on the two sides and the back of the anesthetized mouse, and carrying out active immunization; and performing intraperitoneal injection on the actively immunized mouse by adopting pertussis toxin, and performing final immunization. According to the invention, the renal tubular interstitial nephritis-uveitis syndrome mouse model is successfully constructed, so that a foundation is laid for subsequent pathological mechanism research of the disease, and a support can be provided for further development of medicine research for treating the disease.

The inventor has synthesized 2 '-O > 2-methoxyethyl modified FXYD2-LASO (FXYD2-LASO-gapmer) and injects the 2'-O > 2-methoxyethyl modified FXYD2-LASO and the 2 '-O > 2-methoxyethyl modified FXYD2-LASO-gapmer into the vein, and an application way with relatively small invasiveness is provided. Intravenous administration of the FXYD2 optimized antisense oligonucleotide (LASO) with MOE, compared to intrathecal administration, allows for a long-term effect on pain. The inventors have proven this long term effect on neuropathic pain in spinal nerve ligation (SNL) rat models and inflammatory pain in complete Freund's adjuvant (CFA) induced rat models. Thus, the present invention relates to antisense oligonucleotides targeting FXYD2 for use in the treatment of pain wherein the antisense oligonucleotides are administered intravenously.

The invention relates to the technical field of animal models, and discloses a construction method of a thyroid-associated ophthalmopathy animal model, which comprises the following steps: extracting retroocular soft tissue homogenate of mice, mixing the retroocular soft tissue homogenate with a complete Freund's adjuvant to obtain an emulsifier, carrying out multi-point injection on the mice by using the emulsifier, inducing the mice to generate autoimmune response, and constructing the thyroid-associated ophthalmopathy animal model. And generating the thyroid-associated eye disease rat model. Pathological characteristics of the animal model obtained through construction better conform to clinical pathological characteristics, that is, eye pathological characteristics are obvious, and changes of TSH, TRAb, FT3 and FT4 in serum and pathological changes of eye soft tissue and thyroid tissue conform to pathological changes of thyroid-related eye diseases.

The invention relates to a construction method of a damp-heat downward flow type erectile dysfunction animal model, which comprises the following steps: S1, from the day of modeling, feeding mice with high-sugar and high-fat feed, and simultaneously providing mixed drinking water containing alcohol and honey, free diet and water; s2, from the eighth day of modeling, feeding the mice in a humid and hot environment; s3, on the 15th day, the 20th day and the 25th day of modeling, a prostate tissue emulsion is adopted to conduct subcutaneous injection on the mouse, a cyclophosphamide solution is synchronously injected into the intraperitoneal cavity, and the prostate tissue emulsion is obtained by emulsifying prostate tissue homogenate and a complete Freund's adjuvant according to the volume ratio of 1: 1; and S4, carrying out comprehensive evaluation on the damp-heat downward flow type erectile dysfunction animal model. Internal and external damp-heat factors are combined with drug induction, the pathogenesis of'damp-heat accumulation in lower jiao 'in traditional Chinese medicine is cooperatively simulated through multiple mechanisms, the manifestation symptom of the animal model is almost consistent with the disease symptom of a clinical damp-heat downward flow type impotence patient, and good scientificity and reliability are achieved.

The invention discloses an application of fluorocitric acid Fluorocitrate in preparation of a medicine for treating inflammatory pain, and belongs to the technical field of medicines. According to the invention, a complete Freund's adjuvant induced inflammatory pain model is constructed based on a KM mouse, an astrocyte inhibitor Fluorocitrate is given to the inflammatory pain model on the second day, and the analgesic effect of the Fluorocitrate on the inflammatory pain mouse is evaluated through a behavioral experiment. The result shows that the Flurocitrate can significantly reduce the pain sensitivity of mice with inflammatory pain, which indicates that the Flurocitrate has potential application value in treatment of inflammatory pain and is expected to be developed into a potential therapeutic drug for inflammatory pain.

The invention provides a method for constructing a myositis-related interstitial lung disease mouse model, which comprises the following steps: injecting 10 micrograms of ODN2395 into the abdominal cavity of a female BALB / c mouse, injecting 0.25 mL of a mixed emulsion of SD (Sprague Dawley) rat skeletal muscle homogenate and a complete Freund's adjuvant into each of the two sides of the back of the female BALB / c mouse at the same time point, and feeding for a certain time to obtain a film-formed mouse. The method has the advantages that raw materials are easy to obtain, and the modeling method is simple; 2, the modeling time is relatively short; and 3, the model forming rate is high, and the method is more in line with the pathogenesis and pathological phenotype of IIM-ILD.

The invention belongs to the technical field of construction of disease animal models, and discloses a construction method of a psoriatic arthritis animal model, which adopts zymosan mannan and a complete Freund's adjuvant to jointly induce psoriatic arthritis for modeling. According to the invention, the zymosan mannan and the complete Freund's adjuvant are used for combined induction, so that the typical pathological manifestation of psoriatic arthritis can be stably simulated, and particularly, the model is superior to the existing animal model in the aspect of simultaneously inducing joint inflammation and psoriasis-like skin lesion, and is closer to the pathological characteristics of clinical patients.

The present invention relates to an inhibitor of FXYD2, wherein the inhibitor reduces the expression and / or activity of FXYD2 in a subject in need thereof and targets at least a region comprising or consisting of nucleotides 219 to 229 of SEQ ID NO: 3. The inventors have demonstrated that targeting the FXYD2 region can be used to inhibit and / or reduce the expression and / or activity of FXYD2. They designed and synthesized an antisense oligonucleotide (SEQ ID NO: 4) targeting the rat and human FXYD2 genes. They performed intrathecal injection of the FXYD2-optimized ASO in two rat pain models (neuropathic pain and inflammatory pain). They have demonstrated that FXYD2 ASO can effectively reduce its expression in the rat dorsal root ganglion (DRG). They have demonstrated that FXYD2 ASO can significantly reduce neuropathic pain in the spinal nerve ligation (SNL) rat model, and the analgesic effect of FXYD2 ASO on neuropathic pain is greater than that of the current market leader, ziconotide. They have also shown that FXYD2 ASO can significantly reduce inflammatory pain in a rat model induced by complete Freund's adjuvant (CFA).

The present invention relates to an inhibitor of FXYD2 wherein the inhibitor reduces the expression and / or activity of FXYD2 in a subject in need thereof and targets at least a region comprising or consisting of nucleotides 219-229 of SEQ ID NO: 3. The inventors have demonstrated that targeted FXYD2 regions can be used to inhibit and / or reduce the expression and / or activity of FXYD2. The antisense oligonucleotide (SEQ ID NO: 4) targeting the FXYD2 genes of the rat and the human is designed and synthesized by the FXYD2 genes of the rat and the human. They have been subjected to an intrathecal injection of FXYD2 optimized ASO in two modes of rat pain (neuropathic pain and inflammatory pain). It has been proved that FXYD2 ASO can effectively reduce the expression of FXYD2 ASO in rat dorsal root ganglion (DRG). It has been proved that the FXYD2 ASO can significantly reduce the neuropathic pain in a spinal nerve ligation (SNL) rat model, and the analgesic effect of the FXYD2 ASO on the neuropathic pain is better than that of the leading Zconotide in the current market. The FXYD2 ASO also shows that the FXYD2 ASO can obviously reduce the inflammatory pain in a rat model induced by a complete Freund's adjuvant (CFA).

The utility model discloses a device for promoting full mixing of type II collagen and a freund's adjuvant. The device comprises a container, an injector and a connecting pipe, holes are formed in the two sides of the container, and a low-temperature medium can be injected into the container. The tube bodies of the injectors are arranged inside the container through the hole sites, the operating ends of the injectors are arranged outside the container, and the two injectors are connected through the connecting tube; the outer wall of the tube body of the injector and the tube wall of the connecting tube are coated or wound with a shading material, or the outer wall of the container is coated with a shading material. The syringes are arranged in the holes in the two sides of the container, the low-temperature medium is injected into the container, the outer walls of the tube bodies of the syringes and the tube wall of the connecting tube are coated or wound with the shading materials, or the outer wall of the container is coated with the shading materials, and therefore a low-temperature shading environment is provided to promote fusion.

The invention discloses application of an FABP7 inhibitor in preparation of a medicine for treating inflammatory pain, and belongs to the technical field of medicines. A complete Freund's adjuvant induced inflammatory pain model is constructed based on KM mice, an FABP7 inhibitor MF6 is given to the inflammatory pain model three days later, and the analgesic effect of the FABP7 inhibitor on the inflammatory pain mice is evaluated through behavioral experiments. Results show that the FABP7 inhibitor can significantly reduce the pain sensitivity of mice with inflammatory pain, which indicates that the FABP7 inhibitor has potential application value in treatment of inflammatory pain and is expected to be developed into a potential therapeutic drug for inflammatory pain.

The invention belongs to the technical field of medicines, and relates to a Chinese tamarisk twig alcohol extract with anti-inflammatory activity as well as a preparation method and application thereof, and the Chinese tamarisk twig alcohol extract is one or more of 50% ethanol total extract, 20% ethanol subpart and 40% ethanol subpart of Chinese tamarisk twig. The Chinese tamarisk twig alcohol extract also has any one of the following applications: preparation of a medicine for preventing and treating inflammation in aquaculture, preparation of a medicine for preventing and / or treating fish inflammation, and preparation of a feed in aquaculture. The 50% ethanol extract prepared by the invention has a good improvement effect on a lipopolysaccharide (LPS)-induced zebrafish inflammation model, and has a remarkable treatment effect on rats with rheumatoid arthritis induced by a complete Freund's adjuvant; two new active parts are further prepared, the activity of the active parts is superior to that of total extracts, and the active parts have a remarkable improvement effect on LPS-induced Tg (mpx: EGFP) transgenic zebrafish inflammation and can be used for being developed into new anti-inflammatory traditional Chinese medicines in the future.

The present invention provides an application of Cyclovirobuxinum D (CVB-D) in pharmaceutical preparation, belonging to the technical field of medical drugs. CVB-D has a significant inhibitory effect on Ca v 3.2 Activity of low voltage-gated calcium channels, different ion channels involved in pain transmission in peripheral nociceptors, such as Na v 1.7 Na v 1.8, TRPV1, TPRA1, TRPM8, ASIC3, P 2 X 2 and P 2 X 4 In addition, CVB-D can significantly relieve inflammatory pain induced by carlean gum and complete Freund's adjuvant and neuropathic pain induced by paclitaxel, and its effect is comparable to that of the positive control Z944. v 3.2 Low voltage-gated calcium channel inhibitors.

The application provides a vaccine against ichthyophthiriasis and a preparation method and application thereof, and belongs to the technical field of fish disease prevention and control. The application uses inactivated whole worms of in-vitro large-scale cultured Amphilina alata as a cross antigen, and fish complement C5a protein as an immunoadjuvant, and the two synergistically play a high-efficiency immune protection role. The application mixes and emulsifies the C5a adjuvant and the antigen at an effective dose of 1x10 4 6x10 4 per tail to prepare the vaccine. After intraperitoneal injection and secondary boosting, the vaccine produces significant cross protection against the infection of the ichthyophthirius, and the protection effect is significantly better than that of a traditional Freund's adjuvant vaccine. The application breaks the bottleneck that the ichthyophthirius cannot be cultured in vitro and thus a large number of worm bodies cannot be obtained for large-scale preparation of whole worm vaccines, and also solves the problem of poor safety of traditional adjuvants, has the advantages of low cost, good effect, easy large-scale production and the like, and is suitable for green immune prevention and control of ichthyophthiriasis of freshwater fish.

The application discloses a kind of phenylboronic acid and dopamine grafted chitosan-manganese-based injectable hydrogel immunoadjuvant and its preparation method and application.The hydrogel takes chitosan as base material, constructs modified polymer by chemical grafting dopamine and phenylboronic acid;Manganese ion is loaded to form phenylboronic acid and dopamine grafted chitosan-manganese-based injectable hydrogel immunoadjuvant.The hydrogel is fixed antigen by physical adsorption, has the functions of targeted delivery, immune activation and controllable release, significantly enhances humoral immunity and cellular immunity.The hydrogel has the characteristics of low viscosity, supports simple injection, biodegradable and no local inflammatory reaction.Experiments show that the titer of the adjuvant is equivalent to that of Freund's adjuvant after immunizing mice, successfully used for preparing monoclonal antibody of gladiolus burkholderia, and constructs immune test strip, and the sensitivity reaches 5×10 5 CFU / mL.The application solves the problems of high toxicity, local damage and high cost of traditional adjuvant, and is suitable for vaccine development and immunodiagnosis.